Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Valneva SE    VLA   FR0004056851

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

VIVALIS : MISE A DISPOSITION DU DOCUMENT DE REFERENCE 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 07:35am CET

VIVALIS PUBLIE SON
DOCUMENT DE REFERENCE 2011

Nantes, Lyon (France) - 27 avril 2012 : VIVALIS (NYSE Euronext Paris : VLS), société biopharmaceutique, annonce que son Document de référence 2011 a été déposé le 25 avril 2012 auprès de l'Autorité des Marchés Financiers (AMF) sous le numéro D12-0412.

Des exemplaires du présent Document de Référence sont disponibles sans frais auprès de la Société, au 6, rue Alain Bombard, 44821 Saint-Herblain cedex, ainsi qu'en version électronique sur le site internet de la Société (www.vivalis.com) et  sur le site internet de l'Autorité des marchés financiers (www.amf-france.org:
http://www.amf-france.org/).

Les documents suivants sont notamment intégrés dans le document de référence 2011 :
-       le rapport financier annuel,
-       le rapport du Président du Conseil de surveillance sur les conditions d'organisation et de préparation des travaux du Conseil de surveillance et sur les procédures de contrôle interne mises en place par la Société,
-       les informations relatives aux honoraires versés aux commissaires aux comptes,
-       le document d'information annuel.

VIVALIS MISE A DISPOSITION DU DOCUMENT DE REFERENCE:
http://hugin.info/143334/R/1606613/509370.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: VIVALIS via Thomson Reuters ONE

HUG#1606613
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VALNEVA SE
12/02 VALNEVA : Leading Healthcare Investor MVM Life Science Partners Acquires 7.5% Sh..
12/01 VALNEVA : Leading Healthcare Investor MVM Life Science Partners Acquires 7.5% Sh..
11/24 VALNEVA : Wins "Fastest Growing Listed Company" Tech 50 Award for France by Delo..
11/24 VALNEVA : Wins "Fastest Growing Listed Company" Tech 50 Award for France by Delo..
11/20 VALNEVA : Biotech firm closes in on Zika jab French biotech firm Valneva says it..
11/10 TOTAL : VALNEVA Reports Strong Business Performance in First Nine Months. Compan..
11/09 VALNEVA : Reports Strong Business Performance in First Nine Months, Company Incr..
11/09 VALNEVA : Reports Strong Business Performance in First Nine Months. Company Rais..
11/02 VALNEVA : GE Healthcare and Valneva Collaboration Delivers Optimized Cell Cultur..
09/08 VALNEVA : Announces Signing of Marketing & Distribution Agreement for Seqirus` F..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Financials (€)
Sales 2016 99,1 M
EBIT 2016 -38,7 M
Net income 2016 -46,6 M
Debt 2016 20,9 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 33,50
EV / Sales 2016 2,23x
EV / Sales 2017 1,79x
Capitalization 200 M
More Financials
Chart VALNEVA SE
Duration : Period :
Valneva SE Technical Analysis Chart | VLA | FR0004056851 | 4-Traders
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 4,60 €
Spread / Average Target 72%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Franck Grimaud Chief Executive Officer
Thomas Lingelbach President-Management Board
Frédéric Grimaud Chairman-Supervisory Board
Reinhard Kandera Chief Financial Officer
Klaus Schwamborn Vice President-Discovery Research & Innovation
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VALNEVA SE-29.47%213
INCYTE CORPORATION-7.86%19 219
QUINTILES IMS HOLDINGS..6.32%18 225
CELLTRION, INC.--.--%9 953
SEATTLE GENETICS, INC.48.64%9 442
LONZA GROUP AG11.34%9 247
More Results